KDOQI (Kidney Disease Outcomes Quality Initiative)

NKF K/DOQI GUIDELINES

Executive Summaries | Anemia | Hemodialysis | Peritoneal Dialysis |
Vascular Access | Nutrition | CKD 2002 | Dyslipidemias | Bone Metabolism | Hypertension and Antihypertensive Agents | History of K/DOQI



  K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease

RECOMMENDATIONS FOR CLINICAL PERFORMANCE MEASURES

GUIDELINE 2

Blood pressure should be measured in all CKD patients at each health encounter (Guideline 2.1).

All patients with CKD should have the following information recorded in the medical record (Guideline 2.2):

GUIDELINE 7

All adults with CKD should have a blood pressure that is less than 130/80 mm Hg (Guideline 7.2), unless there is a documented contraindication in the medical record (such as orthostatic hypotension, postprandial hypotension, autonomic dysfunction, or severe peripheral vascular disease that is exacerbated by blood pressure less than 130/80 mm Hg).

GUIDELINE 8

All patients with diabetic kidney disease should be treated with either an ACE inhibitor or an ARB (Guideline 8.2), unless there is a documented contraindication in the medical record (such as pregnancy or a history of allergy; see Table 124).

GUIDELINE 9

All patients with nondiabetic kidney disease and spot urine total protein-to-creatinine ratio ≥200 mg/g) should be treated with either an ACE inhibitor or an ARB (Guideline 9.2), unless there is a documented contraindication in the medical record (such as pregnancy or a history of allergy; see Table 124).

GUIDELINE 13

All children with CKD should have a blood pressure that is less than 130/80 mm Hg or a blood pressure that is less than the 90th percentile for age, height, and weight, whichever is lower (Guideline 13.3), unless there is a documented contraindication in the medical record.